Literature DB >> 4136225

The structure of human high density lipoprotein and the levels of apolipoprotein A-I in plasma as determined by radioimmunoassay.

G Schonfeld, B Pfleger.   

Abstract

The major apoprotein of high density lipoprotein is apolipoprotein A-I (ApoA-I). In addition to being a structural component of this class of lipoproteins, ApoA-I also has a physiologic role as an activator of lecithin-cholesterol acyl transferase, an enzyme important in the metabolism of all lipoproteins. To measure ApoA-I content in human plasma, to assess its immunologic activity in hyperlipoproteinemia, and to carry out certain structural studies of high density lipoproteins, we have developed a double antibody radioimmunoassay. ApoA-I, isolated by gel filtration, was used to produce monospecific antisera. ApoA-I was iodinated by chloramine-T and the resulting [(125)I]-ApoA-I was purified by gel filtration. > 85% of [(125)I]-ApoA-I was precipitated by antibody, and 90% of bound [(125)I]ApoA-I was displaced by "cold" ApoA-I. Other lipoproteins and apoproteins did not react. Plasma and high density lipoprotein from normals and subjects with hyperlipoproteinemia displaced counts in parallel with ApoA-I, suggesting that the same antigenic determinants were reacting with antibody on lipid-free and lipid-associated ApoA-I. However, less than 5% of ApoA-I of high density lipoprotein reacted in the assay. Removal of the lipid by extraction increased the reactivity of ApoA-I in high density lipoprotein 15-20-fold; thus more than 95% of the ApoA-I molecules in "intact" high density lipoprotein are unreactive with antibody. Normal and hyperlipoproteinemic plasma and high density lipoproteins isolated from the same subjects continued to display parallelism with ApoA-I standard after lipid extraction, suggesting that ApoA-I of normal and hyperliproteinemic subjects are immunologically identical. About 90% of ApoA-I was in the d 1.063-1.21 fractions of normal plasma, trace quantities were found in the lipoproteins of d < 1.063, and the rest (about 10%) was in the d > 1.21 fraction. Normal plasma levels, assessed in extracted plasmas with a precision of 8%, were 100+/-35 mg/dl. Levels were normal in small groups of subjects with types II and IV hyperlipoproteinemia and high in pregnancy. However, larger population studies need to be performed to determine the distribution of ApoA-I levels in the various hyperlipoproteinemias.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4136225      PMCID: PMC301550          DOI: 10.1172/JCI107758

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

2.  A human lipoprotein polymorphism.

Authors:  B S BLUMBERG; D BERNANKE; A C ALLISON
Journal:  J Clin Invest       Date:  1962-10       Impact factor: 14.808

3.  Isolation and characterization of apoLp-Gln-II (apoA-II), a plasma high density apolipoprotein containing two identical polypeptide chains.

Authors:  S E Lux; K M John; H B Brewer
Journal:  J Biol Chem       Date:  1972-12-10       Impact factor: 5.157

4.  Studies on the composition and structure of plasma lipoproteins. Distribution of lipoprotein families in major density classes of normal human plasma lipoproteins.

Authors:  P Alaupovic; D M Lee; W J McConathy
Journal:  Biochim Biophys Acta       Date:  1972-04-18

Review 5.  Practical methods for plasma lipoprotein analysis.

Authors:  F T Hatch
Journal:  Adv Lipid Res       Date:  1968

6.  Heterogeneity in protein subunits of human serum high-density lipoproteins.

Authors:  B Shore; V Shore
Journal:  Biochemistry       Date:  1968-08       Impact factor: 3.162

Review 7.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-26       Impact factor: 91.245

8.  Fractionation of human serum high density lipoprotein in urea solutions. Evidence for polypeptide heterogeneity.

Authors:  A Scanu; J Toth; C Edelstein; S Koga; E Stiller
Journal:  Biochemistry       Date:  1969-08       Impact factor: 3.162

9.  Studies on the protein defect in Tangier disease. Isolation and characterization of an abnormal high density lipoprotein.

Authors:  S E Lux; R I Levy; A M Gotto; D S Fredrickson
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

10.  Forms of human serum high density lipoprotein protein.

Authors:  A Scanu
Journal:  J Lipid Res       Date:  1966-03       Impact factor: 5.922

View more
  31 in total

1.  Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Ayokanmi Adeniyi; Aaron R Folsom; Frederick L Brancati; Moise Desvorieux; James S Pankow; Herman Taylor
Journal:  J Natl Med Assoc       Date:  2002-12       Impact factor: 1.798

2.  The composition and metabolism of high density lipoprotein subfractions.

Authors:  E J Schaefer; D M Foster; L L Jenkins; F T Lindgren; M Berman; R I Levy; H B Brewer
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

3.  Apolipoproteins in rat serum and renal lymph.

Authors:  P S Roheim; D Edelstein; G G Pinter
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

4.  The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins.

Authors:  G Assmann; E Smootz; K Adler; A Capurso; K Oette
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

5.  Isolation and partial characterization of high-density lipoprotein HDL1 from rat plasma by gradient centrifugation.

Authors:  L T Lusk; L F Walker; L H DuBien; G S Getz
Journal:  Biochem J       Date:  1979-10-01       Impact factor: 3.857

6.  Effects of dietary polyunsaturated and saturated fat on the properties of high density lipoproteins and the metabolism of apolipoprotein A-I.

Authors:  J Shepherd; C J Packard; J R Patsch; A M Gotto; O D Taunton
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

7.  Apolipoproteins AI, AII, and CI stimulate placental lactogen release from human placental tissue. A novel action of high density lipoprotein apolipoproteins.

Authors:  S Handwerger; S Quarfordt; J Barrett; I Harman
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

8.  Effects of dietary cholesterol and fatty acids on plasma lipoproteins.

Authors:  G Schonfeld; W Patsch; L L Rudel; C Nelson; M Epstein; R E Olson
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

9.  Isolation and characterization of cDNA clones for human apolipoprotein A-I.

Authors:  J L Breslow; D Ross; J McPherson; H Williams; D Kurnit; A L Nussbaum; S K Karathanasis; V I Zannis
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

10.  Radioimmunoassay of human apolipoprotein CII. A study in normal and hypertriglyceridemic subjects.

Authors:  M L Kashyap; L S Srivastava; C Y Chen; C G Perisutti; M Campbell; R F Lutmer; C J Glueck
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.